Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 633 of 5804
-
Personalized blood thinners could cut stroke risk
Disease control Completed1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy an…
Phase: PHASE4 • Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Breath and blood test could spot lung cancer earlier, reduce false positives
Diagnosis Recruiting nowThis is a prospective observational study designed to address the clinical challenge posed by the high false-positive rate associated with CT imaging in early lung cancer screening. The primary objective is to develop a multi-omics technology for early lung cancer screening, lev…
Sponsor: Chen KeZhong • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowThe study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New radiation strategy aims to deepen prostate cancer remission
Disease control Recruiting nowThis will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic…
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThe purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat urinary tract cancer
Disease control Recruiting nowNeoadjuvant chemotherapy treatment can be used for specific UTUC patients, especially for highly staged and/or grade tumors, such as kidneys with potentially decreased renal function after RNU. Neoadjuvant therapy is a series of treatments administered preoperatively for UTUC, ma…
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combination pill aims to tackle Tough-to-Treat high blood pressure
Disease control CompletedThe purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
Phase: PHASE2 • Sponsor: Wuhan Createrna Science and Technology Co., Ltd • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New ADHD pill aims to control symptoms for 16 hours
Disease control CompletedThe goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
Phase: PHASE3 • Sponsor: Cingulate Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug MP0533 takes aim at Hard-to-Treat leukemia
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to cut COPD attacks in heavy smokers
Disease control OngoingThis study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New implant zaps nerve to treat sleep apnea without CPAP
Disease control OngoingThe solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Phase: NA • Sponsor: Nyxoah S.A. • Aim: Disease control
Last updated Jun 26, 2026 14:10 UTC
-
Could a new pill help people who feel sleepy all day?
Symptom relief CompletedThis is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).
Phase: PHASE2 • Sponsor: Zevra Therapeutics • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New shot could cut stroke risk for heart patients who Can't take pills
Disease control Recruiting nowA study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulat…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New pill targets rare genetic cancers in early trial
Disease control Recruiting nowA Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:14 UTC
-
New hope against a deadly parasitic disease: LXE408 shows promise in phase II trial
Disease control CompletedThis is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThe study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013…
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for blood cancer patients: drug aims to slash infection risk
Disease control Recruiting nowThe primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammagl…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug duo offers hope for Hard-to-Treat lymphoma patients
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial
Disease control OngoingThis is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Keytruda shows promise in shrinking untreatable bowel tumors
Disease control OngoingIn this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC